Serious adverse events · people with hepatocellular carcinoma
It is very uncertain whether radioembolisation changes serious adverse events compared with chemoembolisation (very low certainty).
1 finding from 1 review
Cancer‐related mortality at maximal · people with hepatocellular carcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Time to progression of the tumour · people with hepatocellular carcinoma
1 finding from 1 review
Health‐related quality of life · people with hepatocellular carcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Disease control rate · people with hepatocellular carcinoma
1 finding from 1 review
Non‐serious adverse events · people with hepatocellular carcinoma
1 finding from 1 review
Serious adverse events · people with hepatocellular carcinoma
1 finding from 1 review
Cancer‐related mortality at maximal · people with hepatocellular carcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Time to progression of the tumour · people with hepatocellular carcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Tumour response measures · people with hepatocellular carcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Non‐serious adverse events (hyperbilirubinaemia: most frequent) · people with hepatocellular carcinoma
1 finding from 1 review
All‐cause mortality at 1 year · people with hepatocellular carcinoma
1 finding from 1 review
Health‐related quality of life · people with hepatocellular carcinoma
1 finding from 1 review
Overall survival · advanced gastric and oesophago‐gastric junction adenocarcinoma
Chemotherapy probably leads to lower overall survival compared with placebo, best supportive care (BSC) or no treatment (moderate certainty).
1 finding from 1 review
Any adverse events · advanced gastric and oesophago‐gastric junction adenocarcinoma
Biological therapy showed no clear difference in any adverse events compared with placebo, best supportive care (BSC) or no treatment (high certainty).
1 finding from 1 review
QoL · advanced gastric and oesophago‐gastric junction adenocarcinoma
1 finding from 1 review
Overall survival · advanced gastric and oesophago‐gastric junction adenocarcinoma
Chemotherapy showed no clear difference in overall survival compared with biological therapy (moderate certainty).
1 finding from 1 review
Progression‐free survival · advanced gastric and oesophago‐gastric junction adenocarcinoma
Chemotherapy probably leads to higher progression‐free survival compared with biological therapy (moderate certainty).
1 finding from 1 review
Serious adverse events · advanced gastric and oesophago‐gastric junction adenocarcinoma
Chemotherapy may leads to lower serious adverse events compared with biological therapy (low certainty).
1 finding from 1 review
Tumour response · advanced gastric and oesophago‐gastric junction adenocarcinoma
Chemotherapy showed no clear difference in tumour response rate compared with biological therapy (low certainty).
1 finding from 1 review